Yale Cancer Center to Present on the Synergistic Relationship Between Intravenously-Administered SB 11285, Spring Bank’s STING Agonist Development Compound, and Radiation Therapy in Cancer at the 2019 ASTRO Annual Meeting
September 17, 2019 08:00 ET
|
Spring Bank Pharmaceuticals, Inc.
HOPKINTON, Mass., Sept. 17, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of...
Spring Bank Announces $20 Million Strategic Debt Financing Agreement with Pontifax Medison Finance
September 04, 2019 08:00 ET
|
Spring Bank Pharmaceuticals, Inc.
Significant investment demonstrates confidence in Spring Bank’s novel development programs Extends Spring Bank’s cash runway beyond the end of 2021 Accelerates HBV antisense and STING antagonist...
Spring Bank Announces Collaborative Research Agreement with University of Texas Southwestern Medical School for Evaluation of STING Antagonist Compounds
August 06, 2019 08:00 ET
|
Spring Bank Pharmaceuticals, Inc.
HOPKINTON, Mass., Aug. 06, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of...
Spring Bank Pharmaceuticals Reports Second Quarter 2019 Financial and Operational Results and Provides Business Development Update
July 31, 2019 16:30 ET
|
Spring Bank Pharmaceuticals, Inc.
HOPKINTON, Mass., July 31, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of...
Spring Bank Announces FDA Acceptance of IND Application for SB 11285, an IV-Administered STING Agonist, for the Treatment of Advanced Solid Tumors
July 29, 2019 08:00 ET
|
Spring Bank Pharmaceuticals, Inc.
HOPKINTON, Mass., July 29, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of...
Spring Bank Announces Dosing of Inarigivir 400mg In Multiple HBV Studies
July 23, 2019 08:15 ET
|
Spring Bank Pharmaceuticals, Inc.
- First Patient Dosed Ahead of Schedule in Inarigivir 400mg CATALYST 2 Trial - First Patient Completes Dosing in Inarigivir 400mg Intra-Hepatic Liver Biopsy Study - Ongoing Inarigivir +...
Spring Bank Announces Research Agreement with The National Institute of Allergy and Infectious Diseases to Evaluate HBV Antisense Oligonucleotide Compounds
July 18, 2019 11:00 ET
|
Spring Bank Pharmaceuticals, Inc.
HOPKINTON, Mass., July 18, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of...
Spring Bank Pharmaceuticals Announces Election of Pamela Klein, M.D., to its Board of Directors
July 10, 2019 16:00 ET
|
Spring Bank Pharmaceuticals, Inc.
HOPKINTON, Mass., July 10, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of...
Spring Bank Submits IND Application for SB 11285, an IV-Administered STING Agonist, for the Treatment of Advanced Solid Tumors
July 01, 2019 08:00 ET
|
Spring Bank Pharmaceuticals, Inc.
HOPKINTON, Mass., July 01, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of...
Spring Bank to Present Pre-Clinical Data on Its Novel STING Antagonist Program at The Autoimmunity Conference
June 27, 2019 08:30 ET
|
Spring Bank Pharmaceuticals, Inc.
HOPKINTON, Mass., June 27, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of...